Risk Prediction Model for Crohn's Disease Based on Hematological Indicators

Clinical Laboratory
|July 12, 2023
PubMed

Insights

A new model using routine blood tests predicts Crohn's disease (CD) risk. This tool aids in early diagnosis and differentiating CD from conditions like intestinal tuberculosis (ITB).

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Diagnostic Medicine

Background:

  • Diagnostic errors are common when distinguishing Crohn's disease (CD) from other conditions like ulcerative colitis (UC) and intestinal tuberculosis (ITB).
  • An efficient, rapid, and simple predictive model is crucial for clinical application in CD diagnosis.
  • Current diagnostic methods can be invasive and time-consuming, necessitating simpler alternatives.

Purpose of the Study:

  • To develop a risk prediction model for CD using five routine laboratory tests.
  • To create an early warning system and a visual nomograph for CD risk assessment.
  • To provide clinicians with a convenient tool for CD risk determination and differential diagnosis.

Main Methods:

  • Retrospective analysis of 310 cases (2020-2022) including CD, UC, non-IBD diseases, and healthy controls.
  • Risk prediction models were built using logistic regression based on hematological indices: ESR, Hb, WBC, ALb, and CH.
  • Models were evaluated for diagnostic accuracy and visualized using a nomograph.

Main Results:

  • Significant differences in ESR, WBC, and WBC/CH ratios were observed between CD and non-CD groups (p < 0.05).
  • The WBC/CH ratio showed a strong correlation with CD occurrence (correlation coefficient > 0.4).
  • A logistic regression model demonstrated high diagnostic accuracy (AUC=0.86) for CD prediction and (AUC=0.88) for differentiating CD from ITB.

Conclusions:

  • A novel CD risk prediction model was successfully established using five conventional hematological indices.
  • The model, visualized via a nomograph, offers high diagnostic accuracy for CD and its differentiation from ITB.
  • This tool can assist clinicians in better managing CD and reducing patient suffering.
Abstract

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
198
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
298
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175